A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

2020634 citationsJournal Articlebronze Open Access

Authors

Aaron S. Kelly · University of Minnesota Medical Center

Pernille Auerbach · Novo Nordisk (Denmark)

Margarita Barrientos‐Pérez

Inge Gies · Universitair Ziekenhuis Brussel

Paula M. Hale · Novo Nordisk (United States)

Claude Marcus · Karolinska Institutet

Lucy D. Mastrandrea · University at Buffalo, State University of New York

Abstract

In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).

Topics & Keywords

Diabetes Treatment and Management Pharmacology and Obesity Treatment Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-beingNo poverty

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 22, pp. 2117-2128

DOI: 10.1056/nejmoa1916038

Field-Weighted Citation Impact: 41.87